TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).
Lu S, Provencio M, Lisberg A, Mascarenhas E, Tanizaki J, Cheng Y, Kim H, Liu Y, Feng S, Zhang L, Toms L, Yang J, Goldberg S. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8647.Peer-Reviewed Original ResearchProgression-free survivalSafety run-inCentral nervous systemEGFR mutationsPerformance statusSecondary endpointsPhase 3 clinical trial dataEGFR tyrosine kinase inhibitorsRun-inBlinded independent central reviewEGFR mutated NSCLCEGFR mutation typeDuration of responseWHO performance statusIndependent central reviewPhase 3 studyPrimary study endpointTyrosine kinase inhibitorsTopoisomerase I inhibitorAntibody-drug conjugatesMutated NSCLCAdvanced NSCLCIV diseaseNon-squamousOverall survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply